Clinical Trials
21 trialsNCT04685525 2024-04-26
Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT03591614 2023-08-18
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT05393999 2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2 Withdrawn
NCT00900120 2021-09-21
Collecting and Storing Blood Samples From Patients With Cancer
Rutgers, The State University of New Jersey
Withdrawn
NCT04024384 2020-03-27
DARALLO
Assistance Publique - Hôpitaux de Paris
Phase 2 Withdrawn
NCT01647165 2019-12-12
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00085449 2019-11-27
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn
NCT01332617 2017-12-29
Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
University of Louisville
Phase 2 Withdrawn
NCT00504101 2016-12-15
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
University of Miami
Phase 1 Withdrawn
NCT01501370 2016-05-10
ZLd_Ld
University of Turin, Italy
Phase 2 Withdrawn
NCT01016028 2016-05-03
Chemotherapy-Induced Peripheral Neuropathy Survey
M.D. Anderson Cancer Center
Withdrawn
NCT00004040 2015-08-19
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
Hoag Memorial Hospital Presbyterian
Phase 2 Withdrawn
NCT00770419 2015-05-29
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
Rutgers, The State University of New Jersey
Withdrawn
NCT02114502 2014-07-11
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00085345 2013-07-10
Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00112879 2013-07-10
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00968396 2013-04-05
Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00499668 2013-04-02
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
Vanderbilt-Ingram Cancer Center
Phase NA Withdrawn
NCT01101412 2013-02-15
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00301912 2012-10-02
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT01558778 2012-07-09
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Phase NA Withdrawn